



ORAL PRESENTATION

Open Access

Phase 2a safety and immunogenicity testing of DNA and recombinant modified vaccinia ankara virus vaccines expressing virus-like particles

P Goepfert^{1*}, M Elizaga², D Montefiori³, J Hural², S DeRosa², G Tomaras³, K Seaton³, A Sato², L Ouedraogo⁴, Y Donastorg⁵, M Cardinali⁴, J Lama⁶, L Baden⁷, M Keefer⁸, J McElrath⁹, S Kalams¹⁰, H Robinson¹¹

From AIDS Vaccine 2012
Boston, MA, USA. 9-12 September 2012

Background

The Phase 2a HVTN 205 trial was undertaken to further compare full-dose regimens of DNA priming with MVA boosting and MVA priming and boosting.

Methods

150 vaccinia-naïve participants were inoculated i.m. via needle and syringe with 3 mg of pGA2/JS7 DNA at months 0 and 2, and 1x10⁸ TCID₅₀ of MVA/HIV62B at months 4 and 6 (DDMM regimen). 75 participants received 1x10⁸ TCID₅₀ of MVA/HIV62B at months 0, 2, and 6 (MMM regimen) and 75 received placebo. While the safety data are still blinded, the vaccine regimens appeared safe and well tolerated. Immune studies were performed at 2 weeks following the final vaccination.

Results

Similar to Phase 1 testing, the DDMM regimen induced higher rates of T cell responses whereas the MMM regimen induced higher rates of antibody responses. CD4 T cell responses were elicited in 65% of the DDMM and 43% of the MMM recipients ($p=0.01$) whereas CD8 T cells were induced in 22% and 16%, respectively. The majority of T cells were directed against Gag with fewer against Env and only occasional responses to Pol. gp120 IgG antibodies were demonstrated in 45% and 68% of the DDMM and MMM recipients, respectively ($p=0.001$). gp41 IgG antibodies were seen in over 90% of both groups. The magnitudes of serum IgG responses exceeded the magnitudes of serum IgA responses by >10 fold with higher IgG to IgA responses being present in the MMM group

($p=0.03$). The antibody avidity index to the gp41 immunodominant epitope, a preclinical correlate of protection against infection demonstrated levels of affinity maturation comparable to preclinical studies. Sporadic weak neutralizing activity against Tier 1 and Tier 2 viruses was seen in both groups and was greater for MVA alone.

Conclusion

The vaccine safety data and immune responses seen here are supportive of further testing.

Author details

¹University of Alabama at Birmingham, Birmingham, AL, USA. ²Fred Hutchinson Cancer Research Institute, Seattle, WA, USA. ³Duke University, Durham, NC, USA. ⁴NIAID Vaccine Clinical Research Branch, Bethesda, MD, USA. ⁵Unidad de Vacunas IDCP-COIN-DIGECITSS, Santo Domingo, Dominican Republic. ⁶Asociación Civil IMPACTA Salud y Educación, Barranco, Lima, Peru. ⁷Brigham and Women's Hospital, Boston, MA, USA. ⁸University of Rochester, Rochester, NY, USA. ⁹Fred Hutchinson Cancer Research Institute, Seattle, WA, USA. ¹⁰Vanderbilt University, Nashville, TN, USA. ¹¹GeoVax Inc., Smyrna, GA, USA.

Published: 13 September 2012

doi:10.1186/1742-4690-9-S2-O56

Cite this article as: Goepfert *et al.*: Phase 2a safety and immunogenicity testing of DNA and recombinant modified vaccinia ankara virus vaccines expressing virus-like particles. *Retrovirology* 2012 **9**(Suppl 2):O56.

¹University of Alabama at Birmingham, Birmingham, AL, USA
Full list of author information is available at the end of the article